The burgeoning field of metabolic disease management is witnessing a novel convergence of therapies. Semaglutide , a dual GIP/GLP-1 receptor agonist , alongside Retatrutide , a triple GIP/GLP-1/GCG receptor https://wisesocialsmedia.com/story7163057/tirzepatide-and-nad-a-integrated-approach-to-general-health